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Abstract
Background: Pancreatic islet transplantation is a promising treatment for type I diabetes mellitus, but current
immunosuppressive strategies do not consistently provide long-term survival of transplanted islets. We are
therefore investigating the use of adeno-associated viruses (AAVs) as gene therapy vectors to transduce rat islets
with immunosuppressive genes prior to transplantation into diabetic mice.
Results: We compared the transduction efficiency of AAV2 vectors with an AAV2 capsid (AAV2/2) to AAV2
vectors pseudotyped with AAV5 (AAV2/5), AAV8 (AAV2/8) or bovine adeno-associated virus (BAAV) capsids,
or an AAV2 capsid with an insertion of the low density lipoprotein receptor ligand from apolipoprotein E
(AAV2apoE), on cultured islets, in the presence of helper adenovirus infection to speed expression of a GFP
transgene. Confocal microscopy and flow cytometry were used. The AAV2/5 vector was superior to AAV2/2 and
AAV2/8 in rat islets. Flow cytometry indicated AAV2/5-mediated gene expression in approximately 9% of rat islet
cells and almost 12% of insulin-positive cells. The AAV2/8 vector had a higher dependence on the helper virus
multiplicity of infection than the AAV 2/5 vector. In addition, the BAAV and AAV2apoE vectors were superior to
AAV2/2 for transducing rat islets. Rat islets (300 per mouse) transduced with an AAV2/5 vector harboring the
immunosuppressive transgene, tgfβ1, retain the ability to correct hyperglycemia when transplanted into immune-
deficient diabetic mice.
Conclusion: AAV2/5 vectors may therefore be useful for pre-treating donor islets prior to transplantation.
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Background
Type I diabetes mellitus (Type I DM) is an autoimmune
disorder that destroys pancreatic β-cells in the islets of
Langerhans, causing severe insulin deficiency and hyperg-
lycemia. Treatment options include islet transplantation,
but consistent Type I DM correction with this approach
has been elusive, partly due to side-effects of required
immunosuppressive drugs [1-3]. Expression of immuno-
suppressive genes within islets may provide local protec-
tion and reduce the need for immunosuppressive drugs.
Genes, including those encoding CTLA4Ig [4-6], soluble
Fas ligand [6], and transforming growth factor β1 (TGF-
β1) [4,7-9] have been transferred to islets in animal trans-
plantation models. One problem is the gene delivery sys-
tem. Adenoviral vectors provide only transient gene
expression, and there are safety questions with retroviral
and lentiviral vectors.
Vectors based on adeno-associated viruses (AAVs) have
been studied for their abilities to transduce mouse and
human islets, since such vectors may overcome the safety
and efficacy concerns. The best studied AAV is AAV2, a
naturally defective human parvovirus with a 4.7 kb
genome [10]. To replicate, AAV2 usually requires a helper
virus, such as an adenovirus or herpesvirus [11]. AAV2 has
not been associated with a human disease.
There are conflicting reports regarding the ability of AAV2
vectors with an AAV2 capsid (AAV2/2) to transduce effi-
ciently mouse or human islets [12-16]. The abilities of
AAV2 vectors pseudotyped with the capsids of AAV1
(AAV2/1) [13,16,17], AAV5 (AAV2/5) [12,13,15,16], and
AAV8 (AAV2/8) [14,15,17] to transduce murine and
human islets have also been investigated. Another
approach to enhance islet transduction is the insertion of
the low density lipoprotein receptor ligand from apolipo-
protein E into AAV2 capsid proteins (AAV2apoE) [13].
Another roadblock to islet transplantation is the shortage
of human donors. Xenotransplantation is being explored
to overcome this obstacle [7,8,18] and rat to mouse trans-
fer of islets provides a model system. The relative ease of
harvesting large numbers of rat islets, versus murine islets,
also makes the use of rat islets desirable. Therefore, we
examined the transduction of rat islets by pseudotyped
AAV vectors.
Results
Transduction of Rat Islets with AAV Vectors
To determine which AAV capsids more efficiently mediate
transduction, we transduced rat islets with AAV vectors
and simultaneously infected them with Ad5, because
islets can only survive for 1 week in tissue culture, and co-
infection with Ad5 results in less time before AAV vector
transgene expression. As a transduction marker, the eGFP
gene, modified to confer nuclear localization (nls-eGFP),
was included in the vectors.
Rat islets (Figs. 1A–L) were transduced with recombinant
AAV2 genomes harboring the nls-eGFP gene packaged
into AAV2, AAV2apoE, AAV5, or AAV8 capsids at an AAV
MOI of 1.5 × 103 and an Ad5 MOI of 10. At this MOI,
AAV2/2 did not transduce rat islets well (Figs. 1A–C).
AAV2apoE, however, did show a modest ability to trans-
duce rat islets (Figs. 1D–F). The most efficient vector in
this experiment was AAV2/5 (Figs. 1G–I). AAV2/8
appeared to be even less efficient than AAV2/2 at this MOI
(Figs. 1J–L). We were surprised at the relative lack of trans-
duction with the AAV2/8 vector under these conditions,
given previous reports that it was more efficient at mouse
islet transduction than AAV2/2 or AAV2/5 vectors [19,20].
However, increasing the AAV MOI to 1.0 × 104, while
maintaining an Ad5 MOI of 10, did facilitate AAV2/8
transduction of rat islets (Fig. 2C).
Vectors were also tested at an AAV MOI of 1 × 104 and an
Ad5 MOI of 1 (Figs. 3A–F). AAV2/2 again showed mini-
mal transduction (Figs. 3A–B). AAV2/8 also did not trans-
duce rat islets very well at this MOI (Figs. 3E–F), but
significant transduction was achieved with AAV2/5 (Figs.
3C–D), suggesting that the requirement for Ad5 helper
functions for AAV2/5 is less than that of AAV2/8.
Previous works have attempted to quantify transduction
by microscopy. We used a recently developed method for
dispersing islet cells, prior to flow cytometry analysis [21],
which showed that 9% of the AAV2/5- treated islet cells
were positive for GFP (Fig. 3G). AAV2/5 transduced beta-
islet cells, since 6% of the islet cells (12% of insulin+ cells)
were doubly-positive for GFP and insulin. Fewer alpha
cells were transduced than beta cells, as only 1% of cells
were positive for GFP and glucagon (3% of glucagon+
cells).
We also compared rat islets transduced with a recom-
binant AAV2 genome encoding eGFP packaged into the
capsids of AAV2 or BAAV at an AAV MOI of 3.0 × 104 and
an Ad5 MOI of 1 (Figs. 3H–L). The AAV MOI was
increased in this experiment over the MOIs in the other
experiments, because these viruses were purified using
CsCl density gradients while the other viruses had been
purified using an iodixanol gradient followed by ion
exchange or heparin chromatography. AAV vectors puri-
fied by a CsCl gradient exhibit decreased infectivity com-
pared to AAV purified by an iodixanol gradient and
affinity chromatography [22].
The CsCl-purified AAV2/2 vector showed little transduc-
tion of rat islets (Figs. 3J–L). However, approximately
21% of the BAAV-treated islets cells were transduced (Figs.Virology Journal 2009, 6:61 http://www.virologyj.com/content/6/1/61
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Transduction of rat islets with pseudotyped AAV vectors and a high Ad5 MOI Figure 1
Transduction of rat islets with pseudotyped AAV vectors and a high Ad5 MOI. Rat islets were transduced with 
AAV2-nls-eGFP packaged into AAV2 (A-C), AAV2apoE (D-F), AAV5 (G-I) and AAV8 (J-L) capsids at an AAV MOI of 1500 (A-
L). All islets were infected with Ad5 at an MOI of 10. The islets were visualized by confocal microscopy on day 5 after trans-
duction. (A, D, G, J) Fluorescent. (B, E, H, K) Differential interference contrast (DIC). (C, F, I, L) Merged.
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3H, I, L). Furthermore, 13% of the islet cells were doubly-
positive for insulin and eGFP (21% of insulin-positive
cells), suggesting that BAAV can transduce beta-islet cells.
Unlike AAV2/5, BAAV appears to be as efficient at trans-
ducing alpha cells, since 6% of the islet cells (25% of the
glucagon+ cells) were positive for eGFP and glucagon (Fig.
3L).
Xenotransplantation of AAVTGFP2/5-Transduced Rat 
Islets
We wished to assess the practicality of transducing islets
with an AAV vector encoding the immunosuppressive
gene, TGF-β1. It is possible that transduction with an AAV-
TGF-β1 vector might alter islet function. Rat islets were
therefore transduced with an AAV5 pseudotyped vector
harboring the gene for TGF-β1, linked via an internal
ribosome entry site (IRES) to the eGFP gene (AAVTGFP2/
5), at an MOI of 1.0 × 104 and an Ad5 MOI of 1 in vitro.
On day 6 after treatment, transduced islets showed a four-
fold increase in supernatant TGF-β1 levels compared to
control islets infected only with Ad5 (Fig. 4A). Transduced
islets had levels of insulin secretion comparable to islets
infected with Ad5 alone (Fig. 4B). Finally, rat islets (300
per mouse) were transplanted into female, immune-defi-
cient NOD-SCID mice that had been made diabetic with
streptozotocin treatment. The mice became normoglyc-
emic shortly after transplantation of either untreated or
transduced (AAVTGFP2/5 without Ad5) islets and
remained normoglycemic for more than two months (Fig.
4C). Glucose levels continued rising in mice receiving no
islets (Fig. 4C).
Discussion
Vectors were produced containing recombinant AAV2
genomes, harboring the nls-eGFP gene, packaged into the
capsids of AAV2, AAV5, AAV8, BAAV, or an AAV2 capsid
that was modified by inserting a polypeptide containing
the ApoE receptor binding domain of the ApoE ligand
connected to a lipid binding domain [23].
Typically, an Ad5 MOI of 5 has been used for the in vitro
transduction of islets [12,16], but Ad5 MOIs from 1–50
are able to enhance AAV transduction in proportion to the
Ad5 MOI [24]. We tested an Ad5 MOI of 1 to determine if
a low concentration of Ad5 could provide helper func-
tions, while perhaps minimizing Ad5 toxicity. At an Ad5
MOI of 1, transduction of rat islets was more efficient with
the AAV2/5 vector than with the AAV2/2 or AAV2/8 vec-
tors. The platelet-derived growth factor receptor (PDGFR)
is a receptor for AAV5 [25]. PDGFR levels in islets have
been reported to vary between human subjects and are
particularly high in patients with chronic pancreatitis
[26].
Given the unexpectedly poor transduction efficiency of
the AAV2/8 vector, it was deemed necessary to test it in the
presence of a higher Ad5 MOI. Increasing the Ad5 MOI to
10 significantly enhanced AAV2/8 transduction of rat
islets.
Although Ad5 can enhance AAV2 transduction by stimu-
lating AAV2 DNA second-strand synthesis [24,27], Ad5
capsids also facilitate translocation of AAV2 into the
nucleus [28]. Since our AAV2/5 and AAV2/8 vectors have
identical DNA templates, the lower Ad5 MOI is probably
sufficient for second-strand synthesis. Therefore, the
improved transduction of AAV2/8 with an Ad5 MOI of 10
may be due to enhanced nuclear translocation or viral
uncoating. Please note that in vivo experiments with AAV
vectors are usually done in the absence of helper virus,
therefore, relative gene expression in vivo may differ from
that seen in vitro. However, the lower Ad5 MOI should
more closely approximate in vivo conditions without
helper virus.
It has been reported that AAV2/5 vectors can transduce
human islets [16]. This increases the probability that data
obtained with AAV2/5 vectors in rat to mouse transplan-
tations can be translated into patient protocols.
BAAV transduces rat islets relatively well at an Ad5 MOI of
1. However, since BAAV transduced α-islet cells with
about the same efficiency as β-islet cells, the AAV5 capsid
may be better for more selective transduction of β-islet
cells.
Our results suggest that AAVTGFP2/5, encoding TGF-β1,
can transduce islets without altering islet functions in vitro
or in vivo. These data concur with a previous experiment in
which adenovirus vector delivery of TGF-β1 to islets
showed no impact on insulin production, in response to
glucose, in culture [9]. The amount of insulin contributed
Transduction of rat islets with a high MOI of pseudotyped  AAV2/8 vectors and a high Ad5 MOI Figure 2
Transduction of rat islets with a high MOI of pseudo-
typed AAV2/8 vectors and a high Ad5 MOI. Rat islets 
were transduced with AAV2-nls-eGFP packaged into an 
AAV8 capsid at an AAV MOI of 1500 (B) or 10,000 (C). All 
islets were infected with Ad5 at an MOI of 10. (A) Ad5 only. 
The islets were visualized by fluoresence confocal micros-
copy on day 5 after transduction.
A                             B                             CVirology Journal 2009, 6:61 http://www.virologyj.com/content/6/1/61
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by the serum used to prepare the culture medium was
small (< 0.1 ng/ml final concentration) compared to the
amount produced by the islets. An immunodeficient dia-
betic mouse model was chosen for transplantation to
allow better analysis of direct toxicity from TGF-β1. Our
mice receiving AAVTGFP2/5-transduced islets became
normoglycemic for at least 2 months. Previous studies of
AAV vectors with islets showed transgene expression
within 2–4 weeks [12,15]. We therefore assume that the
TGF-β1 gene was expressed for at least 4 weeks. We had
hoped that the eGFP gene within AAVTGFP2/5 would
allow us to confirm gene expression, but the eGFP signal
was too weak to detect reliably, even under tissue culture
conditions (not shown).
Conclusion
Infection of rat islets with AAV2/5 vectors allows relatively
efficient transgene expression with no significant adverse
effects on in vivo islet function. TGF-β1, expressed from an
AAV2/5 vector, does not appear to have a negative impact
Transduction of rat islets with pseudotyped AAV vectors at high AAV MOIs and a low Ad5 MOI Figure 3
Transduction of rat islets with pseudotyped AAV vectors at high AAV MOIs and a low Ad5 MOI. Rat islets were 
transduced with AAV2-nls-eGFP packaged into the capsids of AAV2 (A, B, J, K), AAV5 (C, D), AAV8 (E, F) or BAAV (H, I), at 
an AAV MOI of 10,000 (A-G) or 30,000 (H-L) and an Ad5 MOI of 1 (A-L). The islets were visualized by confocal microscopy 
on day 5 after transduction. (A, C, E, H, J) Fluorescent. (B, D, F, I, K) DIC. On day 6, flow cytometry analysis was performed on 
dispersed islet cells (G, L), including negative controls infected with Ad5 only. AAV vectors used in panels A-G were purified 
on iodixanol gradients. AAV vectors used in panels H-L were purified on cesium chloride gradients.
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Transduction of rat islets with AAVTGFP2/5 Figure 4
Transduction of rat islets with AAVTGFP2/5. (A) In vitro expression of TGF-beta 1 in conditioned medium taken on day 
6 after transduction of rat islets with AAVTGFP2/5 (plus infection with Ad5) as measured by ELISA. As a negative control, 
islets were infected with Ad5 only. The error bars indicate the standard deviation. (B) Insulin secretion in vitro from rat islets 
transduced with AAVTGFP2/5 and infected with Ad5. Insulin levels in conditioned medium on day 6 after transduction were 
measured by radioimmunoassay. As a negative control, rat islets were infected with Ad5 only. The error bars indicate the 
standard deviation. (C) Blood glucose levels of NOD-SCID mice transplanted with transduced rat islets. Islets were isolated 
from Wistar rats and transduced with AAVTGFP2/5. Transduced islets were then transplanted into diabetic NOD-SCID mice 
(TGF). Other NOD-SCID mice were either transplanted with mock-transduced islets or sham operated. The error bars indi-
cate the standard error (n = 6).
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on rat islet function. AAV2/5 vectors may therefore be use-
ful for pre-treating donor islets prior to transplantation.
Methods
Cell Culture
Packaging of AAV2 genomes into AAV2, AAV2apoE, AAV5
and AAV8 capsids used HEK 293 cells (Stratagene; La
Jolla, CA). Cells were maintained at 37°C with a humidi-
fied environment containing 5% CO2, in Dulbecco's
Modified Eagle Medium (Invitrogen; Carlsbad, CA) with
10% fetal bovine serum (FBS) (Invitrogen).
Packaging of AAV Vectors
Plasmid pAAV2-nls-EGFP contains the enhanced green
fluorescent protein gene, modified to contain a nuclear
localization sequence (nls-eGFP), controlled by the
human cytomegalovirus major immediate-early pro-
moter, flanked by the AAV2 inverted terminal repeats
(ITRs). At 24 h before transfection, twenty 15-cm diameter
plates were each seeded with 1.7 × 107 HEK 293 cells. For
transfection, 360 μg of pAAV2-nls-EGFP, 1.08 mg of
pHelper (Stratagene), and 360 μg of either pAAV-RC
(Stratagene), pAAV2apoE (described below), p5E18-VD2/
8 [29] (from Dr. James Wilson, University of Pennsylva-
nia, USA), or pXR5 [30] (from Dr. R. Jude Samulski, Uni-
versity of North Carolina, USA) were added to 25 ml of
0.3 M CaCl2. Plasmids pAAV-RC, p5E18-VD2/8 and pXR5
contain AAV genes necessary for packaging AAV2
genomes into AAV2, AAV8 and AAV5 capsids, respec-
tively, and pHelper contains adenovirus 5 (Ad5) genes
required for helper functions. Twenty-five milliliters of 2×
HBS (280 mM NaCl, 1.5 mM Na2 PO4, 50 mM HEPES, pH
7.05), prewarmed to 37°C, was added to the plasmid/
CaCl2  solution, and the mixture was incubated for 1
minute at room temperature. Next, this mixture was
added to 400 ml of pre-warmed DMEM with 10% FBS and
22 ml of this medium was added to each 15-cm diameter
plate. Virus was purified by the method of Zolotukhin, et
al. [22,31]. In brief, after 48 hours, the cells were har-
vested by centrifugation at 1140 × g for 10 minutes and
the supernatant was discarded. The virus was released by
three freeze-thaw cycles, then purified on an iodixanol
gradient, followed by either heparin affinity (AAV2 and
AAV2apoE) or ion exchange (AAV2/5 and AAV2/8) chro-
matography.
The BAAV-eGFP vector was produced and purified using a
cesium chloride gradient, as described previously [32]. A
batch of AAV2/2-eGFP vector, used for comparison, was
purified by the same method.
Construction of pAAV2apoE
We inserted the ApoE ligand into the AAV2 capsid using
overlapping PCR mutagenesis to introduce AscI and PacI
restriction sites for the cloning of the DNA encoding the
ligand into the capsid gene. The mutagenic primers were
5'ggcgcgccttaattaacgtcttaacaggttcc3' (M1) and 5'ttaattaag-
gcgcgccgctccgggaaaaaagaggc' (M2). PCR was performed
with two separate reactions. In reaction 1, pAAVRC was
used as a template and primers M1 and
5'ggacgtacgggagctggtacttccg3' were used for amplification.
In reaction 2, the same template and primers M2 and
5'gatttaaatcaggtatggctgccg3' were used. The PCR fragments
from these reactions were gel purified, annealed to each
other, and extended with pfu Ultra DNA polymerase
(Stratagene). The resulting fragment was cut with BsiWI
and SwaI, and ligated into the corresponding sites of pAA-
VRC to make pAAVRCKI. Next, oligonucleotides contain-
ing the sequence for the ApoE ligand
(LRKLRKRLLRDWLKAFYDKVAEKLKEAF) (synthesized by
Integrated DNA Technologies; Coralville, Iowa, USA),
flanked by AscI and PacI sites, were annealed, cut with
AscI and PacI, and inserted into the corresponding sites of
pAAVRCKI to make pAAV2apoE. Loiler et.  al. reported
improved transduction of islets with an AAV2 vector by
insertion of a similar peptide [13]. Our peptide was mod-
ified by substituting lysine residues for aspartic acid resi-
dues at positions 23 and 25, since the lipid binding
domain is a class A amphipathic α-helix, which is charac-
terized by positively charged residues at these positions
[33].
Construction of pAAVTGFP
The rat TGF-β1 gene was PCR amplified from plasmid
TGFβ33 (from Dr. Anita Roberts, National Cancer Insti-
tute) and cloned into pEGFPIRES (Clontech; Mountain
View, California, USA), which contains an eGFP gene
downstream of an internal ribosome entry site (IRES). The
primers that amplified the TGF-β1 gene introduced an
EcoRV site on the 5' end of the gene and an Eco RI site on
the 3' end. The 5' primer was
5'attcgatatcggcgccgcctcccccatgccg3' and the 3' primer was
5'attcgaattccggggcctcagctgcacttgcagg3'. The PCR parame-
ters were: 2 minutes at 95°C; then 30 cycles of 95°C for
30 seconds, 55°C for 30 seconds, and 72°C for 1 minute
and 12 seconds; then a final 10 minute extension period
at 72°C.
After gel purification, the TGF-β1 fragment and pEGF-
PIRES were digested with EcoRI and EcoRV (New England
Biolabs; Ipswich, Massachusetts, USA) and ligated to form
pTGFP. Next, the expression cassette from pTGFP, con-
taining the TGF-β1 and eGFP genes, was amplified by PCR
using the primers 5'attagcggccgccgggccagatatacgcgttga3'
and 5'attagcggccgctcttacgtgagctcggggtc3', which included
NotI sites. PCR conditions were the same as above, with
pTGFP as the template. The PCR product was digested
with NotI and ligated to the NotI fragment of pAAVLacZ
(Stratagene) containing the AAV2 ITRs, creating pAAVT-Virology Journal 2009, 6:61 http://www.virologyj.com/content/6/1/61
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GFP. Packaging of pAAVTGFP into the AAV5 capsid was
then done using the method described above.
Determination of viral titers
For titration of packaged virus genomes, DNA was iso-
lated from 27.8 μl of the final virus solution. The volume
was adjusted to 100 μl with 10 mM Tris-HCl [pH 7.5], 1
mM EDTA. Next, 10 μl of DNase buffer (500 mM Tris-
HCL, pH 7.5; 100 mM MgCl2), and 10 U of DNase I
(Roche Applied Science; Indianapolis, Indiana, USA) was
added and the solution was incubated at 37°C for 1 hr.
Next, 10 μl of proteinase K buffer (100 mM Tris-HCl, pH
8.0; 100 mM EDTA; 10% SDS) was added with 18.6 μg of
proteinase K (Invitrogen). The solution was incubated for
1 hr at 37°C. Proteins were removed by two phenol-chlo-
roform extractions and one chloroform extraction. The
DNA was ethanol precipitated with 10 μg of glycogen
(Roche). The DNA was resuspended in water and dot blot
hybridization was performed using linearized pAAV2-nls-
EGFP as standards.
Adenovirus type 5 was a kind gift from Dr. Irving Miller
(National Institutes of Health). It was purified on cesium
chloride gradients and titered by plaque assays as
described previously [34].
Isolation of Rat Islets
Wistar rats were euthanized by CO2 inhalation. Next, 10
ml of a 0.25 mg/ml solution of Liberase RI (Roche) in
DMEM was injected into the common bile duct. Each
pancreas was removed, placed in a 50 ml tube and incu-
bated at 37°C for 25 min. After the incubation, 40 ml of
cold DMEM + 10% FBS was added. Tubes were shaken
vigorously for 5–10 sec by hand to break up the tissue. The
rest of the isolation was done at room temperature. Tubes
were centrifuged at 1000 rpm for 1 min, the supernatant
was poured off, 35 ml of DMEM (without serum) was
added and vortexed gently. Centrifugation was repeated
and the supernatant was discarded. The tissue was resus-
pended in 10 ml of DMEM and filtered through a wire
mesh with 1.5 mm holes to remove the remaining undi-
gested tissue, fat and lymph. An additional 5 ml of DMEM
was added to the original tube to wash out any remaining
islets and the wash was also filtered through the wire
mesh. This filtrate was then filtered through a wire mesh
with 0.8 mm holes, then centrifuged at 1200 rpm for 90
sec. The supernatant was aspirated and the pellet was
resuspended in 20 ml of Ficoll and overlain with 10 ml of
DMEM. The sample was spun for 15 min at 1900 rpm.
The topmost layer of media was aspirated. The islet layer
was then collected from the interface with a 10 ml pipette
and placed in a new 50 ml tube. The islets were washed
several times with DMEM and resuspended in 10 ml of
DMEM. Islets were hand picked for later procedures.
Islet Transductions
All islet transductions were performed at least in duplicate
and were done on the day of isolation. The multiplicity of
infection (MOI) was based on an average of 1000 cells per
islet. Fifty islets per well were placed in a 24-well, glass-
bottomed, tissue culture plate with 13 mm diameter
microwells (MatTek Corp.; Ashland, Massachusetts, USA)
in CMRL-1066 medium (Invitrogen) with 10% FBS. The
volumes of the viral preps were adjusted with Lactated
Ringer's Solution before being suspended in CMRL (with-
out FBS) at a final volume of 300 μl. The medium was
aspirated from the islets, and the islets were resuspended
in the viral suspensions. Islets were then incubated at
37°C for two hours. Following incubation, 700 μl of
CMRL with 10% FBS was added per well.
On day 5 after transduction the islets were viewed on an
LSM410 laser scanning confocal microscope (Carl Zeiss;
Thornwood, New York, USA) with a 488/568 krypton-
argon omnichrome laser (Melles Griot; Carlsbad, Califor-
nia, USA). Individual optical sections of GFP-expressing
islets were collected at 1 micron optical thickness using
488 nm excitation, a 20× neofluar lens at zoom 2.5 and a
BP 515–540 nm emission filter. In some cases 1 micron
optical sections were collected at every 0.5 micron focus
step through the islet and reconstructed into a maximum
projection of the entire islet by LSM410 software.
On day 6 after transduction the islets were dispersed into
single cells by incubation in PBS buffer (without Mg++ or
Ca++) for 10 minutes at room temperature. The percent-
ages of GFP+, insulin+, and glucagon+ cells were deter-
mined by flow cytometry, as described previously [21,35].
Insulin in conditioned medium from islet cultures was
detected using a radio immunoassay kit (Linco Research,
Inc.; St. Charles, Missouri). TGF-β1 in conditioned
medium was detected with an enzyme-linked immuno-
sorbent assay (ELISA) kit (Alpco diagnostics, Salem, New
Hampshire, USA).
Transplantation of Transduced Islets into NOD-SCID mice
To ensure that mice became diabetic at approximately the
same time, female NOD-SCID mice were treated with 40
mg/kg streptozotocin (Sigma) freshly dissolved in citrate
buffer (pH 4.5), injected intraperitoneally once a day for
4–5 days. Blood glucose was measured daily using a Glu-
cometer Elite XL (Bayer Corp. Elkhart, Indiana, USA). At
day 7, after the mice became diabetic (blood glucose of
250–450 mg/dl), 300 rat islets, that were transduced with
AAVTGFP2/5 at an MOI of 15,000 (without helper virus),
were transplanted under the kidney capsule of 6 mice. As
negative controls, 6 mice were transplanted with mock-
transduced islets, and 6 mice were opened by a dorsal
incision and closed without receiving islets (Sham oper-Virology Journal 2009, 6:61 http://www.virologyj.com/content/6/1/61
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ated). Blood samples were collected at various times for
glucose testing. All in vivo procedures were approved by
the NIDDK animal care and use committee.
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